Treatment Options, Regulatory Pathways and Global Patterns of Use for Cardiac Implantable Devices in Patients With Titanium Allergy

Background Titanium hypersensitivity is an uncommon but important challenge in patients requiring cardiac implantable electronic devices (CIEDs). Reactions are difficult to predict, often mimic infection, and complicate timely diagnosis. Methods We reviewed diagnostic considerations, therapeutic strategies, regulatory pathways, and global distribution of coated devices. Data sources included prior case reports, regulatory guidelines, and industry distribution records. Results Management options range from conservative observation to prophylactic implantation of hypoallergenic devices. Gold‐coated and polymer‐coated alternatives are effective but constrained by production costs, lack of reimbursement, and limited availability. In the United States, access is possible through custom device and compassionate use pathways, both requiring extensive regulatory approvals. Globally, most requests originate from the U.S. and Europe, with fewer from other regions due to economic and cultural barriers. Conclusions Improved awareness, streamlined regulatory frameworks, and multidisciplinary collaboration are essential to expand access and optimize outcomes for patients with titanium hypersensitivity.